SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    IsaacsonPG, ChottA, NakamuraS, et al, eds. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: SwerdlowSH, CampoE, HarrisNL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008: 214-217.
  • 2
    Campo E, Pileri SA, Jaffe ES, et al. Nodal marginal zone lymphoma. In: SwerdlowSH, CampoE, HarrisNL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008: 218-219.
  • 3
    Isaacson PG, Piris MA, Berger F, et al. Splenic B-cell marginal zone lymphoma. In: SwerdlowSH, CampoE, HarrisNL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008: 185-187.
  • 4
    Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer. 2004; 4: 644-653.
  • 5
    Sagaert X, De Wolf-Peeters C, Noels H, et al. The pathogenesis of MALT lymphomas: where do we stand? Leukemia. 2007; 21: 389-396.
  • 6
    Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposal for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008; 22: 487-495.
  • 7
    Arcaini L, Lucioni M, Boveri E, et al. Nodal marginal zone lymphoma: current knowledge and future directions of a heterogeneous disease. Eur J Haematol. 2009; 83: 165-173.
  • 8
    Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006; 107: 4643-4649.
  • 9
    Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology. 1992; 102: 1628-1638.
  • 10
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 1361-1392.
  • 11
    JaffeES, HarrisN, SteinH, VardimanJW, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001.
  • 12
    Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31: 1860-1861.
  • 13
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244.
  • 14
    [no authors listed]. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329: 987-994.
  • 15
    Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004; 104: 1258-1265.
  • 16
    Papaxoinis G, Fountzilas G, Rontogianni D, et al. Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2008; 19: 780-786.
  • 17
    Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003; 101: 2489-2495.
  • 18
    Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1999; 17: 2486-2492.
  • 19
    Arcaini L, Paulli M, Burcheri S, et al. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol. 2007; 136: 301-304.
  • 20
    Oh SY, Ryoo BY, Kim WS, et al. Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol. 2006; 85: 781-786.
  • 21
    Kojima M, Inagaki H, Motoori T, et al. Clinical implications of nodal marginal zone B-cell lymphoma among Japanese: study of 65 cases. Cancer Sci. 2007; 98: 44-49.
  • 22
    Arcaini L, Paulli M, Boveri E, et al. Marginal zone-related neoplasms of splenic and nodal origin. Haematologica. 2003; 88: 80-93.
  • 23
    Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003; 120: 759-764.
  • 24
    Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002; 3: 41-47.
  • 25
    Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer. 2004; 101: 2050-2057.
  • 26
    Raderer M, Wohrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol. 2006; 24: 3136-3141.
  • 27
    de Boer JP, Hiddink RF, Raderer M, et al. Dissemination patterns in non-gastric MALT lymphoma. Haematologica. 2008; 93: 201-206.
  • 28
    Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000; 95: 802-806.
  • 29
    Oh SY, Ryoo BY, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol. 2007; 82: 446-452.
  • 30
    Camacho FI, Algara P, Mollejo M, et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol. 2003; 27: 762-771.
  • 31
    [no authors listed]. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int. 2000; 50: 696-702.